Asked by: Joani Reid (Independent - East Kilbride and Strathaven)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will make a statement on the availability of covid booster vaccinations to lung cancer patients receiving a targeted therapy.
Answered by Sharon Hodgson - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to protecting those most vulnerable to COVID-19 through vaccination, as guided by the independent Joint Committee on Vaccination and Immunisation (JCVI). The primary aim of the national COVID-19 vaccination programme remains the prevention of serious illness, resulting in hospitalisations and deaths, arising from COVID-19.
The focus of the JCVI advised programme is targeted vaccination of the two groups who continue to be at higher risk of serious disease, including mortality. These are older adults and individuals who are immunosuppressed.
Health is largely devolved and decisions about the organisation and delivery of vaccination services, including who to vaccinate, are matters for each nation to decide. For England, the Government has accepted the JCVI advice for spring 2026 and in line with the advice, a COVID-19 vaccination is being offered to the following groups:
- adults aged 75 years old and over;
- residents in care homes for older adults; and
- individuals aged six months old and over who are immunosuppressed.
The COVID-19 chapter of the UK Health Security Agency Green Book on vaccination and immunisation sets out details of who should be included in these categories. The eligibility criteria for immunosuppression include immunosuppression due to disease or treatment. This includes patients undergoing chemotherapy leading to immunosuppression and patients undergoing radical radiotherapy.
As with all vaccination programmes, the JCVI continues to keep the COVID-19 vaccination programme under review.
Asked by: Joani Reid (Independent - East Kilbride and Strathaven)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the availability of Bedrocan oil.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
Bedrocan oils are a range of unlicensed cannabis-based products for medicinal use. These products have not been assessed by the Medicines and Healthcare products Regulatory Agency (MHRA) for safety, quality, or efficacy, or assessed by National Institute of Health and Care Excellence (NICE) for clinical and cost effectiveness.
Bedrocan, and other unlicensed cannabis-based products for medicinal use, are available from independent providers across the United Kingdom, regulated by the Care Quality Commission. Unlicensed cannabis-based products for medicinal use can only be prescribed by, or under the direction of, a clinician on the General Medical Council Specialist Register. Prescribers of unlicensed medicines have increase medico-legal responsibilities and are responsible for the quality and availability of the medicine prescribed.
These products are not routinely prescribed on the National Health Service, as clinical guidelines from the NICE demonstrate a clear need for further evidence on the safety and effectiveness of unlicensed cannabis-based medicines to support prescribing decisions.
The National Institute for Health and Care Research (NIHR) has issued two calls for research proposals and a highlight notice on medicinal cannabis. Manufacturers, including those for Bedrocan oils, are responsible for generating evidence to support the use of these products and to seek regulatory approval. The Government encourages manufacturers to do so and offers scientific and research advice from the MHRA and the NIHR.